Last reviewed · How we verify

Ferric Carboxymaltose (FCM) — Competitive Intelligence Brief

Ferric Carboxymaltose (FCM) (Ferric Carboxymaltose (FCM)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intravenous iron replacement agent. Area: Hematology.

marketed Intravenous iron replacement agent Iron (Fe³⁺) delivery; transferrin and ferritin binding Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Ferric Carboxymaltose (FCM) (Ferric Carboxymaltose (FCM)) — American Regent, Inc.. Ferric carboxymaltose delivers iron directly into the bloodstream as a stable iron-carbohydrate complex that is taken up by iron-binding proteins to replenish depleted iron stores.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ferric Carboxymaltose (FCM) TARGET Ferric Carboxymaltose (FCM) American Regent, Inc. marketed Intravenous iron replacement agent Iron (Fe³⁺) delivery; transferrin and ferritin binding
intravenous iron carboxymaltose intravenous iron carboxymaltose University of Zurich marketed Intravenous iron replacement agent Iron (Fe³⁺) delivery system; transferrin receptor-mediated uptake
SFP SFP Rockwell Medical Technologies, Inc. marketed Intravenous iron replacement agent Iron (Fe3+) for hemoglobin synthesis and erythropoiesis
Iron Carboxymaltose Iron Carboxymaltose Albina Nowak, MD marketed Intravenous iron replacement agent Iron(III) ion; transferrin and ferritin (iron-binding proteins)
Iron Sucrose (Venofer) Iron Sucrose (Venofer) American Regent, Inc. marketed Intravenous iron replacement agent
IK-3001 IK-3001 Mallinckrodt phase 3 Intravenous iron replacement agent Iron (Fe3+) delivery system
FCM FCM AMAG Pharmaceuticals, Inc. phase 3 Intravenous iron replacement agent Iron (Fe3+) delivery via transferrin-mediated uptake

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Intravenous iron replacement agent class)

  1. American Regent, Inc. · 2 drugs in this class
  2. AMAG Pharmaceuticals, Inc. · 1 drug in this class
  3. Albina Nowak, MD · 1 drug in this class
  4. Mallinckrodt · 1 drug in this class
  5. Rockwell Medical Technologies, Inc. · 1 drug in this class
  6. University of Zurich · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ferric Carboxymaltose (FCM) — Competitive Intelligence Brief. https://druglandscape.com/ci/ferric-carboxymaltose-fcm. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: